Reticular dysgenesis (RD) is a severe congenital immunodeficiency characterized by a maturation arrest in the myeloid lineage and global impairment of lymphoid maturation. 1, 2 The lack of neutrophils is responsible for severe infections early in life. In contrast to other variants of severe combined immunodeficiency (SCID) with neutropenia, 3 in RD no sustained responses to myeloid growth factor have been observed. 4 Several years ago an association with bilateral sensorineural deafness was reported in 88% of the RD cases described. 5 So far, the genetic defect in RD has not been identified and the only curative treatment described is allogeneic stem cell transplantation (SCT). The first successful SCT for RD was reported in 1983. 6 From the small number of cases described, it can be concluded that the use of a myeloablative conditioning regime before SCT is necessary for sustained stable engraftment. 7 Here, we describe a case of a premature and dysmature infant, weighing 1700 g at first SCT, with RD undergoing successful unrelated cord blood transplantation.
Patient was born at 33 4-7 weeks weighing 1100 g (Po3) after an emergency caesarean section because of decelerations on the cardiotocogram (CTG) associated with preeclampsia. At routine laboratory testing at the neonatal care unit a combined granulopenia (0.00 Â 10 9 /l) and lymphopenia (0.07 Â 10 9 /l) was noted (haemoglobin 5.8 mmol/l, leucocytes 0.5 Â 10 9 /l, monocytes 0.11 Â 10 9 /l and thrombocytes 104 Â 10 9 /l). At just over 1 month of age, the bone marrow showed a maturation arrest in the myeloid and lymphoid lineage and there was no response to granulocyte-colony stimulating factor (G-CSF). In addition, she had abnormal brain stem-evoked response audiometry tests, compatible with bilateral sensorineural deafness. Therefore, she was diagnosed with RD. 5 At this time, she had no infectious problems and because of excellent clinical condition at the age of almost 2 months, weighing nearly 1700 g, she underwent an unrelated cord blood transplantation. In view of the extremely low weight, prematurity and the uncertainty of busulfan kinetics in this infant, the risk of a full myeloablative conditioning regimen was considered too high. Despite the risk of being not fully myeloablative, because of the relatively large surface area in a pre-dysmature infant, we reduced the intensity by recalculating 14 g/m 2 treosulfan to mg/kg, using a final dose of 500 mg/kg/day treosulfan for 3 days in combination with fludarabine 25 mg/m 2 /day for 4 days. To conform to the European infant neuroblastoma protocol for infants below 5 kg, we reduced the fludarabine concentration by 33% (normal dose 150 mg/m 2 ). The cord blood graft used was six of six matched (according to Rubinstein criteria on HLA-A and -B serology and DR on high resolution) and consisted of 10 6 CD34 þ cells/kg and 30 Â 10 7 nucleated cells/kg. She received our standard institutional prophylactic antibiotics consisting of ciprofloxacin, cefazoline and fluconazole. Co-trimoxazol was given as Pneumocystis jiroveci prophylaxis from day þ 16 (out of aplasia). No veno-occlusive disease (VOD) prophylaxis was given. As GvHD-prophylaxis, prednisone 1 mg/kg/day was given for 1 month and tapered for 2 weeks before being discontinued. Cyclosporin A (target concentration 150 ng/l) was given for 3 months and tapered thereafter over 2 months. G-CSF was initiated at day þ 7 and stopped on day þ 20.
A complete erythrodermia was observed from days 6 to 17, most probably on the basis of engraftment, alternatively associated with the use of treosulfan. Antihistamines were given for symptomatic relief; there was no need for increasing steroids. Neutrophil engraftment (4500 Â 10 6 /l for 3 days) was achieved on day þ 16. Whole blood chimerism showed 100% donor signal (using variable number tandem repeats (VNTR)). She received a total number of two erythrocyte and four thrombocyte transfusions. No complications were noted.
From approximately 2 months after transplantation a gradual decrease in neutrophils was noted. Four months post-transplantation (aged 6 months) she became neutropenic again. Lymphocyte counts were normal (100% donor). Chimerism in the bone marrow showed 60% patient signal (VNTR) and an absolute maturation arrest in the myeloid lineage. Despite high dosage of G-CSF no increase in granulocytes was seen in the peripheral blood indicating a graft failure. By the time she reached the age of 8 months, she was in good clinical condition and weighed over 5 kg. She underwent a second unrelated cord blood transplantation following a myeloablative conditioning regimen using intravenous busulfan 320 mg/m 2 (over 4 days: target 17.500 mg/l Â h per day) in combination with cyclophosphamide 200 mg/kg plus antithymocyte globulin (ATG-Genzyme) 10 mg/kg. The graft used was five of six matched (locus A mismatch) consisting of 17 Â 10 7 nucleated cells/kg and 9 Â 10 5 CD34 þ cells/kg. Antibiotic prophylaxis and G-CSF was given as during the first SCT. As GvHD prophylaxis she received cyclosporin A (target concentration 200 ng/l) for 6 months, subsequently tapered over 3 months. Prednisone was given as during the first SCT. Neutrophil engraftment (4500 Â 10 showed 100% donor signal (VNTR). The transplantation was complicated by (1) VOD, successfully treated with defibrotide and diuretics and (2) a pseudomonas-associated line-sepsis. She received a total number of eight erythrocyte and 26 thrombocyte transfusions. The high number of thrombocyte transfusions was mainly due to the complicating VOD. No GvHD was noted. Currently, 1 year after her second SCT, the patient is in good clinical condition, free from prophylactic antibiotics, GvHD-and immunosuppressive treatment and her whole blood cell counts have normalized (haemoglobin 7.8 mmol/l, leucocytes 12.3 Â 10 9 /l, granulocytes 6.5 Â 10 9 /l, lymphocytes 2.5 Â 10 9 /l and thrombocytes 394 Â 10 9 /l). She is of short stature (À3 s.d. of average) and weighs 7330 g. Her caloric intake, which can be poor after SCT 8 is adequate. We could not demonstrate gastrointestinal infections/GvHD or malabsorption and her neuropsychological development is normal.
SCT is the only curative therapy for patients with RD. There is only limited experience with SCT for RD, but the published cases favour the use of a myeloablative conditioning regimen prior to SCT. 7 Our patient is different from the patients described so far because she was extremely premature and dysmature at diagnosis. For this reason, we chose a reduced-intensity conditioning regimen using (1) treosulfan instead of busulfan, which is known for its toxic effects on liver and nervous system and (2) fludarabine instead of cyclophosphamide. We realized there was a great chance of (secondary) graft-failure after SCT with a reduced intensity conditioning regimen. However, we speculated that this SCT would give our patient sufficient immunity for at least a few months to mature and gain weight to be able to undergo a myeloablative conditioning regimen. Indeed the first SCT resulted in gradual graft failure. She had grown enough though and was in good enough clinical condition to undergo a second full-ablative SCT resulting in persistent full donor chimerism. The short stature observed here remains unexplained. It was not observed in the follow-up of (only 4) patients successfully treated so far. 6, 7 As our patient has a very rare disease and had two consecutive SCTs, the long-term follow-up, especially for late term effects, is essential. This is the first report on successful SCT for RD in a premature and dysmature neonate. It shows that SCT in premature and dysmature neonates is feasible (and low toxic) using a conditioning regimen with fludarabine and treosulfan. 
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